Prazosin Hydrochloride, Capsules, USP, 1 mg recall — FDA D-0104-2026
CGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit for the above specified lots.